

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  
**November 29, 2019**

---

**MILESTONE PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

---

**Québec**  
(state or other jurisdiction of incorporation)

**001-38899**  
(Commission File Number)

**Not applicable**  
(I.R.S. Employer Identification No.)

**1111 Dr. Frederik-Philips  
Boulevard, Suite 420  
Montréal, Québec CA**  
(Address of principal executive offices)

**H4M 2X6**  
(Zip Code)

Registrant's telephone number, including area code: **(514) 336-0444**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

**Title of each class**  
Common Shares

**Trading Symbol(s)**  
MIST

**Name of each exchange on which registered**  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**

On November 29, 2019, Marco Boorsma notified Milestone Pharmaceuticals Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), including any committees of the Board, effective November 29, 2019. Mr. Boorsma’s resignation from the Board is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MILESTONE PHARMACEUTICALS INC.**

By: /s/ Amit Hasija  
Amit Hasija  
Chief Financial Officer

Dated: December 3, 2019

---